EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

DNA Methylation of POMC and NR3C1-1F and Its Implication in Major Depressive Disorder and Electroconvulsive Therapy

Hannah B Maier, Nicole Moschny, Franziska Eberle, Kirsten Jahn, Thorsten Folsche, Rasmus Schülke, Stefan Bleich, Helge Frieling, Alexandra Neyazi

Pharmacopsychiatry · 01.03.2023 · 56 (02) · 64-72

DOI: 10.1055/a-2034-6536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.03.2023. Verfasst von Hannah B Maier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Major Depressive Disorder, Electroconvulsive Therapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PRACTIS-Clinician Scientist Program of Hannover Medical School, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Precision medicine in psychiatry is still in its infancy. To establish patient-tailored treatment, adequate indicators predicting treatment response are required. Electroconvulsive therapy (ECT) is considered one of the most effective options for pharmacoresistant major depressive disorder (MDD), yet remission rates were reported to be below 50%.

Methods

Since epigenetics of the stress response system seem to play a role in MDD, we analyzed the DNA methylation (DNAm) of genes encoding the glucocorticoid receptor (NR3C1) and proopiomelanocortin (POMC) through Sanger Sequencing. For analysis, blood was taken before and after the first and last ECT from MDD patients (n=31), unmedicated depressed controls (UDC; n=19, baseline), and healthy controls (HC; n=20, baseline).

Results

Baseline DNAm in NR3C1 was significantly lower in UDCs compared to both other groups (UDC: 0.014(±0.002), ECT: 0.031(±0.001), HC: 0.024(±0.002); p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderElectroconvulsive TherapyHumansPro-OpiomelanocortinDNA MethylationEpigenesis, GeneticTreatment OutcomeReceptors, Glucocorticoid

Substanzen

Pro-OpiomelanocortinNR3C1 protein, humanReceptors, Glucocorticoid

Autor:innen und Institutionen

  • Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Hannover, Germany.
  • Laboratory for Molecular Neuroscience, Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Hannover, Germany.
  • Department of Psychiatry and Psychotherapy, Otto von Guericke University Magdeburg (OVGU), Germany.

Förderung

  • PRACTIS-Clinician Scientist Program of Hannover Medical School
  • Deutsche Forschungsgemeinschaft (DFG, German Research Foundation

Zitieren

APA

Maier, H. B., Moschny, N., Eberle, F., Jahn, K., Folsche, T., Schülke, R., Bleich, S., Frieling, H., & Neyazi, A. (2023). DNA Methylation of POMC and NR3C1-1F and Its Implication in Major Depressive Disorder and Electroconvulsive Therapy. Pharmacopsychiatry, 56(02), 64-72. https://doi.org/10.1055/a-2034-6536

Vancouver

Maier HB, Moschny N, Eberle F, Jahn K, Folsche T, Schülke R, et al. DNA Methylation of POMC and NR3C1-1F and Its Implication in Major Depressive Disorder and Electroconvulsive Therapy. Pharmacopsychiatry. 2023;56(02):64-72. doi:10.1055/a-2034-6536

BibTeX
@article{Maier2023,
  author = {Maier, Hannah B and Moschny, Nicole and Eberle, Franziska and Jahn, Kirsten and Folsche, Thorsten and Schülke, Rasmus and Bleich, Stefan and Frieling, Helge and Neyazi, Alexandra},
  title = {DNA Methylation of POMC and NR3C1-1F and Its Implication in Major Depressive Disorder and Electroconvulsive Therapy},
  journal = {Pharmacopsychiatry},
  year = {2023},
  volume = {56},
  number = {02},
  pages = {64--72},
  doi = {10.1055/a-2034-6536}
}
Kostenlos starten →